Jump to main content
Jump to site search


Polymer micro/nanocarrier-assisted synergistic chemohormonal therapy for prostate cancer

Author affiliations

Abstract

Hormotherapy and chemotherapy are still the most important palliative therapeutic approaches for androgen-sensitive prostate cancer (PCa). Recently, the combination of hormotherapy and chemotherapy, namely, chemohormonal therapy has aroused considerable attention. Although synergistic chemohormonal therapy can improve PCa suppression efficacy and prolong the lives of patients, it also leads to severe adverse effects, that is, hormonal tolerance caused by hormotherapy, and leukemia or neutropenia caused by chemotherapy. Therefore, alleviating the adverse effects and improving anti-PCa efficacy are the focuses of the chemohormonal therapy for future researches. In this study, the commercial androgen-deprivation therapy (ADT), polyester microsphere Enantone (ENT), and polypeptide micelles loaded with a clinical antitumor agent mitoxantrone (MTO) are employed for micro/nanocarrier-assisted chemohormonal therapy. Encouragingly, the combined chemohormonal therapy significantly boosts antitumor efficacy and ameliorates side effects in preclinical assessments. With these benefits, the micro/nanocarrier-assisted chemohormonal therapy can be incorporated as an efficient clinical strategy for PCa patients.

Graphical abstract: Polymer micro/nanocarrier-assisted synergistic chemohormonal therapy for prostate cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 15 Feb 2018, accepted on 20 Mar 2018 and first published on 21 Mar 2018


Article type: Paper
DOI: 10.1039/C8BM00190A
Citation: Biomater. Sci., 2018, Advance Article
  •   Request permissions

    Polymer micro/nanocarrier-assisted synergistic chemohormonal therapy for prostate cancer

    L. He, W. Xu, X. Wang, C. Wang, J. Ding and X. Chen, Biomater. Sci., 2018, Advance Article , DOI: 10.1039/C8BM00190A

Search articles by author

Spotlight

Advertisements